Bemdaneprocel (stem-cell-derived neurons)
Phase 3: large human trials
An experimental cell transplant that places lab-grown dopamine neurons into the brain. Early safety results were encouraging; a larger trial is planned.
- Stage: Phase 1 complete, Phase 3 planned
- Type: Disease-modifying
- Developer: BlueRock Therapeutics (a Bayer company)
- Target: Dopamine cell replacement
- How it works: Lab-grown dopamine-producing nerve cells surgically placed into the brain to replace cells lost to Parkinson's.
- Who it's for: People with moderately advanced Parkinson's.
- Key trials: NCT04802733
- Last reviewed: 2026-06-01
What it is
Rather than replacing the chemical dopamine with a drug, this approach replaces the cells that make it. Dopamine-producing neurons are grown from stem cells and surgically implanted into the part of the brain affected by Parkinson's, with the goal of restoring function for the long term.
Where it stands
A small Phase 1 safety study reported that the procedure was generally safe and that implanted cells appeared to survive, with exploratory hints of motor improvement at one year. The developers have announced plans to move to a larger, properly controlled trial.
What the data shows so far
The Phase 1 study enrolled roughly a dozen people and was designed mainly to test safety, not whether it works. Reported motor improvements are from a small, uncontrolled group and could partly reflect the placebo effect, which is strong in Parkinson's surgical studies. A randomized, sham-controlled trial is needed.
What families should know
Cell therapy is one of the most exciting long-term ideas in Parkinson's, but it is still experimental, involves brain surgery, and is years from being widely available, if it succeeds at all. Beware clinics that offer 'stem cell cures' for Parkinson's today. Those are not the same thing and are not proven.
Caveats
Efficacy is unproven. Phase 1 was a small, uncontrolled safety study. Involves brain surgery and immune-suppressing medication. Surgical Parkinson's trials have a large placebo effect, so only a sham-controlled trial can show real benefit.
Timeline
Most recent first.
- 2023-2024, Phase 1 reported safe with exploratory motor signals.
- 2021, Phase 1 safety trial begins.
Sources
Last reviewed: 2026-06-01. Back to the Parkinson's drug pipeline